세계의 유전자 벡터 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2023-2030년)

The global demand for Gene Vector Market is presumed to reach the market size of nearly USD 3160.79 MN by 2030 from USD 993.72 MN in 2022 with a CAGR of 13.72% under the study period 2023 - 2030.

A gene vector is a tool used to transfer genetic material into cells, tissues, or organs in order to alter or replace their genetic makeup. Gene vectors are commonly used in genetic engineering, gene therapy, and biotechnology research. There are several types of gene vectors, including viral and non-viral vectors. Viral vectors are derived from viruses and can be used to deliver genetic material to cells in a highly efficient manner. Examples of viral vectors include retroviruses, adenoviruses, and lentiviruses. Non-viral vectors, on the other hand, are typically made from DNA or RNA and are less efficient than viral vectors. Examples of non-viral vectors include plasmids, liposomes, and nanoparticles. Gene vectors are used in a wide range of applications, including gene therapy, where they are used to deliver healthy genes to cells in order to treat genetic diseases. They are also used in research to study gene function, create transgenic organisms, and develop new biotechnology products.

Market Dynamics:

The rising incidence of genetic disorders, such as cancer, cystic fibrosis, and sickle cell anaemia, is driving the demand for gene vectors. Gene vectors are used in gene therapy, a promising approach for treating genetic disorders by delivering healthy genes to cells. Ongoing advancements in gene therapy technology, such as the development of safer and more efficient gene vectors, are driving the growth of the gene vector market. This includes the use of viral vectors, such as lentiviruses and adeno-associated viruses, which have improved safety and efficacy profiles. There is a significant amount of investment being made in gene therapy research by governments, private companies, and research institutions. This is driving the development of new gene therapies and the use of gene vectors as key tools in their delivery. Personalized medicine, which involves tailoring treatment to an individual's specific genetic makeup, is a growing trend in healthcare. Gene vectors are a critical tool in delivering personalized medicine, which is driving their adoption. There is increasing awareness and acceptance of gene therapy among patients, healthcare providers, and regulatory bodies. This is driving the adoption of gene vectors as a key tool in gene therapy.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of gene vector. The growth and trends of gene vector industry provide a holistic approach to this study.

Market Segmentation:

This section of the gene vector market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Vector Type

• Lentivirus
• Adenovirus
• Adeno-Associated Virus (AAV)
• Plasmid DNA
• Others

By Application

• Gene Therapy
• Vaccinology
• Others

By Disease

• Genetic Disorder
• Cancer
• Infectious Disease
• Others

By End-User

• Scientific Research
• CRO
• CDMO
• Others (Pharmaceutical, Biotechnology Companies)

Regional Analysis

This section covers the regional outlook, which accentuates current and future demand for the Gene Vector market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the gene vector market include Lonza, Merck KGaA, Oxford Biomedica, CGT Catapult, Charles River Laboratories, uniQure N.V., FUJIFILM Diosynth Biotechnologies, Spark Therapeutics, Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . GENE VECTOR - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Vector Type
  • 3.7.2 Market Attractiveness Analysis By Application
  • 3.7.3 Market Attractiveness Analysis By Disease
  • 3.7.4 Market Attractiveness Analysis By End-user
  • 3.7.5 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL GENE VECTOR MARKET ANALYSIS BY VECTOR TYPE

• 6.1 Overview by Vector Type
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Vector Type
• 6.4 Lentivirus Historic and Forecast Sales by Regions
• 6.5 Adenovirus Historic and Forecast Sales by Regions
• 6.6 Adeno-associated Virus (AAV) Historic and Forecast Sales by Regions
• 6.7 Plasmid DNA Historic and Forecast Sales by Regions
• 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL GENE VECTOR MARKET ANALYSIS BY APPLICATION

• 7.1 Overview by Application
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Application
• 7.4 Gene Therapy Historic and Forecast Sales by Regions
• 7.5 Vaccinology Historic and Forecast Sales by Regions
• 7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL GENE VECTOR MARKET ANALYSIS BY DISEASE

• 8.1 Overview by Disease
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Disease
• 8.4 Genetic Disorder Historic and Forecast Sales by Regions
• 8.5 Cancer Historic and Forecast Sales by Regions
• 8.6 Infectious Disease Historic and Forecast Sales by Regions
• 8.7 Others Historic and Forecast Sales by Regions

9 . GLOBAL GENE VECTOR MARKET ANALYSIS BY END-USER

• 9.1 Overview by End-user
• 9.2 Historical and Forecast Data
• 9.3 Analysis by End-user
• 9.4 Scientific Research Historic and Forecast Sales by Regions
• 9.5 CRO Historic and Forecast Sales by Regions
• 9.6 CDMO Historic and Forecast Sales by Regions
• 9.7 Others (Pharmaceutical, Biotechnology Companies) Historic and Forecast Sales by Regions

10 . GLOBAL GENE VECTOR MARKET ANALYSIS BY GEOGRAPHY

• 10.1. Regional Outlook
• 10.2. Introduction
• 10.3. North America Sales Analysis
  • 10.3.1. Overview, Historic and Forecast Sales Analysis
  • 10.3.2. North America By Segment Sales Analysis
  • 10.3.3. North America By Country Sales Analysis
  • 10.3.4. United State Sales Analysis
  • 10.3.5. Canada Sales Analysis
  • 10.3.6. Mexico Sales Analysis
• 10.4. Europe Sales Analysis
  • 10.4.1. Overview, Historic and Forecast Sales Analysis
  • 10.4.2. Europe by Segment Sales Analysis
  • 10.4.3. Europe by Country Sales Analysis
  • 10.4.4. United Kingdom Sales Analysis
  • 10.4.5. France Sales Analysis
  • 10.4.6. Germany Sales Analysis
  • 10.4.7. Italy Sales Analysis
  • 10.4.8. Russia Sales Analysis
  • 10.4.9. Rest Of Europe Sales Analysis
• 10.5. Asia Pacific Sales Analysis
  • 10.5.1. Overview, Historic and Forecast Sales Analysis
  • 10.5.2. Asia Pacific by Segment Sales Analysis
  • 10.5.3. Asia Pacific by Country Sales Analysis
  • 10.5.4. China Sales Analysis
  • 10.5.5. India Sales Analysis
  • 10.5.6. Japan Sales Analysis
  • 10.5.7. South Korea Sales Analysis
  • 10.5.8. Australia Sales Analysis
  • 10.5.9. Rest Of Asia Pacific Sales Analysis
• 10.6. Latin America Sales Analysis
  • 10.6.1. Overview, Historic and Forecast Sales Analysis
  • 10.6.2. Latin America by Segment Sales Analysis
  • 10.6.3. Latin America by Country Sales Analysis
  • 10.6.4. Brazil Sales Analysis
  • 10.6.5. Argentina Sales Analysis
  • 10.6.6. Peru Sales Analysis
  • 10.6.7. Chile Sales Analysis
  • 10.6.8. Rest of Latin America Sales Analysis
• 10.7. Middle East & Africa Sales Analysis
  • 10.7.1. Overview, Historic and Forecast Sales Analysis
  • 10.7.2. Middle East & Africa by Segment Sales Analysis
  • 10.7.3. Middle East & Africa by Country Sales Analysis
  • 10.7.4. Saudi Arabia Sales Analysis
  • 10.7.5. UAE Sales Analysis
  • 10.7.6. Israel Sales Analysis
  • 10.7.7. South Africa Sales Analysis
  • 10.7.8. Rest Of Middle East And Africa Sales Analysis

11 . COMPETITIVE LANDSCAPE OF THE GENE VECTOR COMPANIES

• 11.1. Gene Vector Market Competition
• 11.2. Partnership/Collaboration/Agreement
• 11.3. Merger And Acquisitions
• 11.4. New Product Launch
• 11.5. Other Developments

12 . COMPANY PROFILES OF GENE VECTOR INDUSTRY

• 12.1. Top Company Share Analysis
• 12.2. Market Concentration Rate
• 12.3. Lonza
  • 12.3.1. Company Overview
  • 12.3.2. Company Revenue
  • 12.3.3. Products
  • 12.3.4. Recent Developments
• 12.4. Merck KGaA
  • 12.4.1. Company Overview
  • 12.4.2. Company Revenue
  • 12.4.3. Products
  • 12.4.4. Recent Developments
• 12.5. Oxford Biomedica
  • 12.5.1. Company Overview
  • 12.5.2. Company Revenue
  • 12.5.3. Products
  • 12.5.4. Recent Developments
• 12.6. CGT Catapult
  • 12.6.1. Company Overview
  • 12.6.2. Company Revenue
  • 12.6.3. Products
  • 12.6.4. Recent Developments
• 12.7. Charles River Laboratories
  • 12.7.1. Company Overview
  • 12.7.2. Company Revenue
  • 12.7.3. Products
  • 12.7.4. Recent Developments
• 12.8. uniQure N.V.
  • 12.8.1. Company Overview
  • 12.8.2. Company Revenue
  • 12.8.3. Products
  • 12.8.4. Recent Developments
• 12.9. FUJIFILM Diosynth Biotechnologies
  • 12.9.1. Company Overview
  • 12.9.2. Company Revenue
  • 12.9.3. Products
  • 12.9.4. Recent Developments
• 12.10. Spark Therapeutics Inc.
  • 12.10.1. Company Overview
  • 12.10.2. Company Revenue
  • 12.10.3. Products
  • 12.10.4. Recent Developments

 *Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies